Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.99
TEVA PHARMACEUTICAL INDUSTRIES LTD incurred senior notes of €800,000,000 aggregate principal amount of 7.375% Sustainability-Linked Senior Notes due 2029; €500,000,000 aggregate pr with The Bank of New York Mellon, as trustee at 7.375% per annum (2029 Euro Notes); 7.875% per annum (2031 Euro Notes and 2029 U maturing September 15, 2029 for the 2029 Euro Notes and 2029 USD Notes; September 15, 2031 for the 2031 USD Notes and 2031 Euro Notes.
- Instrument
- senior notes
- Principal
- €800,000,000 aggregate principal amount of 7.375% Sustainability-Linked Senior Notes due 2029; €500,000,000 aggregate pr
- Counterparty
- The Bank of New York Mellon, as trustee
- Rate
- 7.375% per annum (2029 Euro Notes); 7.875% per annum (2031 Euro Notes and 2029 U
- Maturity
- September 15, 2029 for the 2029 Euro Notes and 2029 USD Notes; September 15, 2031 for the 2031 USD Notes and 2031 Euro Notes
- Event
- incurrence
Exact text from the filing
On March 9, 2023, (i) Teva Pharmaceutical Finance Netherlands II B.V. (“ Teva Finance II ”), a wholly owned subsidiary of Teva Pharmaceutical Industries Limited (the “ Company ”), issued €800,000,000 aggregate principal amount of 7.375% Sustainability-Linked Senior Notes due 2029 (the “ 2029 Euro Notes ”) and €500,000,000 aggregate principal amount of 7.875% Sustainability-Linked Senior Notes due 2031 (the “ 2031 Euro Notes ” and, together with the 2029 Euro Notes, the “ Euro Notes ”); and (ii) Teva Pharmaceutical Finance Netherlands III B.V. (“ Teva Finance III ” and, together with Teva Finance II, the “ Issuers ”), a wholly owned subsidiary of the Company, issued $600,000,0000 aggregate principal amount of 7.875% Sustainability-Linked Senior Notes due 2029 (the “ 2029 USD Notes ”) and $500,000,000 aggregate principal amount of 8.125% Sustainability-Linked Senior Notes due 2031 (the “ 2031 USD Notes ” and, together with 2029 USD Notes, the “ USD Notes ” and together with the Euro Note
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
TEVA PHARMACEUTICAL INDUSTRIES LTD entered into Senior Indenture dated March 14, 2018 as supplemented by Fourth Supplemental Indenture dated March 9, 2023 with The Bank of New York Mellon valued at €800,000,000 of 7.375% Sustainability-Linked Senior Notes due 2029; €500,000,000 of 7.875% Sustainab (effective 2023-03-09).
- Action
- entry
- Agreement
- notes offering
- Counterparty
- The Bank of New York Mellon
- Value
- €800,000,000 of 7.375% Sustainability-Linked Senior Notes due 2029; €500,000,000 of 7.875% Sustainab
- Effective
- 2023-03-09
Exact text from the filing
On March 9, 2023, (i) Teva Pharmaceutical Finance Netherlands II B.V. (“ Teva Finance II ”), a wholly owned subsidiary of Teva Pharmaceutical Industries Limited (the “ Company ”), issued €800,000,000 aggregate principal amount of 7.375% Sustainability-Linked Senior Notes due 2029 (the “ 2029 Euro Notes ”) and €500,000,000 aggregate principal amount of 7.875% Sustainability-Linked Senior Notes due 2031 (the “ 2031 Euro Notes ” and, together with the 2029 Euro Notes, the “ Euro Notes ”); and (ii) Teva Pharmaceutical Finance Netherlands III B.V. (“ Teva Finance III ” and, together with Teva Finance II, the “ Issuers ”), a wholly owned subsidiary of the Company, issued $600,000,0000 aggregate principal amount of 7.875% Sustainability-Linked Senior Notes due 2029 (the “ 2029 USD Notes ”) and $500,000,000 aggregate principal amount of 8.125% Sustainability-Linked Senior Notes due 2031 (the “ 2031 USD Notes ” and, together with 2029 USD Notes, the “ USD Notes ” and together with the Euro Note
View on SEC.gov